[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fg9_WmgN657PaUn-5HRuC9Icvfbk9aX2OdkZqULWBpZY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":34,"phaseBuckets":79,"rows":86},"Cancer Research UK",[4,6],"Cancer Research UK, Glasgow",84,false,14,15,47993,21,3,[15,18,21,23,25,27,29,32],{"name":16,"count":17},"Lymphoma",12,{"name":19,"count":20},"Breast Cancer",7,{"name":22,"count":20},"Cancer",{"name":24,"count":20},"Haematological Malignancy",{"name":26,"count":20},"Solid Tumour",{"name":28,"count":20},"Colorectal Neoplasms",{"name":30,"count":31},"Unspecified Adult Solid Tumor, Protocol Specific",6,{"name":33,"count":31},"Ovarian Cancer",[35,40,45,50,54,59,64,68,72,75],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05057013","A Phase I\u002FIIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours","2025-11","HMBD-001",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03096054","A CR-UK Phase I Trial of LY3143921","2027-02-28","LY3143921 hydrate",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05944237","HTL0039732 in Participants With Advanced Solid Tumours","2027-06","HTL0039732",{"nctId":51,"briefTitle":52,"date":48,"intervention":53},"NCT05272709","TT-702 in Patients With Advanced Solid Tumours.","TT-702",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06045910","A Phase I\u002FII Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies","2028-02","ALETA-001",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05722886","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol","2029-10","Alectinib",{"nctId":65,"briefTitle":66,"date":62,"intervention":67},"NCT06988475","DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations","Capmatinib",{"nctId":69,"briefTitle":70,"date":62,"intervention":71},"NCT05786716","DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With HER2 Amplification or Activating Mutations","Trastuzumab",{"nctId":73,"briefTitle":74,"date":62,"intervention":63},"NCT05770037","DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With ALK Positive Cancers",{"nctId":76,"briefTitle":77,"date":62,"intervention":78},"NCT05768178","DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","Vemurafenib",[80,81,82,83,84,85],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[87,127,156,183,208,227,245,273,291,316,334,363,381,413,439,470,488,521,539,561,579,607,677,703,746,774,796,818,840,863,881,906,924,942,960,987,1069,1110,1149,1184,1214,1244,1270,1296,1322,1357,1383,1409,1461,1487,1521,1543,1574,1599,1617,1635,1661,1679,1697,1723,1755,1773,1791,1809,1827,1845,1863,1881,1905,1923,1941,1966,1984,2002,2020,2038,2056,2074,2098,2127,2145,2163,2181,2204,2237,2266,2290,2313,2331,2355,2380,2405,2423,2446,2469,2487,2505,2523,2548,2573,2591,2609,2627,2653,2671,2689,2713,2740,2763,2788,2814,2836,2911,2957,2987,3009,3031,3049,3067,3085,3103,3121],{"intervention":63,"totalTrials":88,"cells":89},2,{"EARLY_PHASE1":90,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":123,"NA":125},{"trials":91,"activeCount":92},[],0,{"trials":94,"activeCount":92},[],{"trials":96,"activeCount":92},[],{"trials":98,"activeCount":88,"soonestReadout":62},[99,110],{"nctId":60,"briefTitle":61,"status":100,"phases":101,"primaryCompletion":62,"completion":62,"start":102,"enrollment":103,"conditions":104,"interventions":105},"RECRUITING",[82,83],"2023-03-01",825,[24,26],[63,106,107,108,109,67],"Atezolizumab","Entrectinib","Trastuzumab in combination with pertuzumab","Vemurafenib in combination with cobimetinib",{"nctId":73,"briefTitle":74,"status":100,"phases":111,"primaryCompletion":62,"completion":62,"start":112,"enrollment":113,"conditions":114,"interventions":122},[82,83],"2023-12-18",30,[24,115,116,117,118,22,119,16,120,121,26],"Malignant Neoplasm","Lymphoproliferative Disorders","Neoplasms by Histologic Type","Neoplasms by Site","Anaplastic Large Cell Lymphoma","Renal Cell Carcinoma","Neuroblastoma",[63],{"trials":124,"activeCount":92},[],{"trials":126,"activeCount":92},[],{"intervention":106,"totalTrials":88,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":152,"NA":154},{"trials":130,"activeCount":92},[],{"trials":132,"activeCount":92},[],{"trials":134,"activeCount":92},[],{"trials":136,"activeCount":88,"soonestReadout":62},[137,141],{"nctId":60,"briefTitle":61,"status":100,"phases":138,"primaryCompletion":62,"completion":62,"start":102,"enrollment":103,"conditions":139,"interventions":140},[82,83],[24,26],[63,106,107,108,109,67],{"nctId":142,"briefTitle":143,"status":100,"phases":144,"primaryCompletion":62,"completion":62,"start":145,"enrollment":113,"conditions":146,"interventions":151},"NCT05770102","DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition",[82,83],"2023-10-25",[147,115,116,117,118,22,28,148,149,150],"Malignancy","Endometrial Neoplasms","Melanoma","Solid Tumours",[106],{"trials":153,"activeCount":92},[],{"trials":155,"activeCount":92},[],{"intervention":107,"totalTrials":88,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":179,"NA":181},{"trials":159,"activeCount":92},[],{"trials":161,"activeCount":92},[],{"trials":163,"activeCount":92},[],{"trials":165,"activeCount":88,"soonestReadout":62},[166,170],{"nctId":60,"briefTitle":61,"status":100,"phases":167,"primaryCompletion":62,"completion":62,"start":102,"enrollment":103,"conditions":168,"interventions":169},[82,83],[24,26],[63,106,107,108,109,67],{"nctId":171,"briefTitle":172,"status":100,"phases":173,"primaryCompletion":62,"completion":62,"start":174,"enrollment":113,"conditions":175,"interventions":178},"NCT05770544","DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With ROS1 Gene Fusion-Positive Cancers.",[82,83],"2025-11-30",[24,147,115,116,117,118,22,176,149,177,26],"Brain Neoplasms","Glioma",[107],{"trials":180,"activeCount":92},[],{"trials":182,"activeCount":92},[],{"intervention":67,"totalTrials":88,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":204,"NA":206},{"trials":186,"activeCount":92},[],{"trials":188,"activeCount":92},[],{"trials":190,"activeCount":92},[],{"trials":192,"activeCount":88,"soonestReadout":62},[193,197],{"nctId":60,"briefTitle":61,"status":100,"phases":194,"primaryCompletion":62,"completion":62,"start":102,"enrollment":103,"conditions":195,"interventions":196},[82,83],[24,26],[63,106,107,108,109,67],{"nctId":65,"briefTitle":66,"status":100,"phases":198,"primaryCompletion":62,"completion":62,"start":199,"enrollment":113,"conditions":200,"interventions":203},[82,83],"2024-11-19",[26,24,115,117,118,22,147,177,121,201,202],"Gastric Cancer","Soft Tissue Sarcoma",[67],{"trials":205,"activeCount":92},[],{"trials":207,"activeCount":92},[],{"intervention":108,"totalTrials":209,"cells":210},1,{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":223,"NA":225},{"trials":212,"activeCount":92},[],{"trials":214,"activeCount":92},[],{"trials":216,"activeCount":92},[],{"trials":218,"activeCount":209,"soonestReadout":62},[219],{"nctId":60,"briefTitle":61,"status":100,"phases":220,"primaryCompletion":62,"completion":62,"start":102,"enrollment":103,"conditions":221,"interventions":222},[82,83],[24,26],[63,106,107,108,109,67],{"trials":224,"activeCount":92},[],{"trials":226,"activeCount":92},[],{"intervention":109,"totalTrials":209,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":241,"NA":243},{"trials":230,"activeCount":92},[],{"trials":232,"activeCount":92},[],{"trials":234,"activeCount":92},[],{"trials":236,"activeCount":209,"soonestReadout":62},[237],{"nctId":60,"briefTitle":61,"status":100,"phases":238,"primaryCompletion":62,"completion":62,"start":102,"enrollment":103,"conditions":239,"interventions":240},[82,83],[24,26],[63,106,107,108,109,67],{"trials":242,"activeCount":92},[],{"trials":244,"activeCount":92},[],{"intervention":71,"totalTrials":209,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":269,"NA":271},{"trials":248,"activeCount":92},[],{"trials":250,"activeCount":92},[],{"trials":252,"activeCount":92},[],{"trials":254,"activeCount":209,"soonestReadout":62},[255],{"nctId":69,"briefTitle":70,"status":100,"phases":256,"primaryCompletion":62,"completion":62,"start":257,"enrollment":113,"conditions":258,"interventions":267},[82,83],"2023-03-07",[24,28,259,260,261,262,263,264,265,266,26],"Urinary Bladder Neoplasm","Gallbladder Neoplasms","Salivary Gland Neoplasm","Lung Neoplasm","Pancreatic Neoplasm","Ovarian Neoplasms","Prostatic Neoplasm","Skin Neoplasm",[71,268],"Pertuzumab",{"trials":270,"activeCount":92},[],{"trials":272,"activeCount":92},[],{"intervention":268,"totalTrials":209,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":287,"NA":289},{"trials":276,"activeCount":92},[],{"trials":278,"activeCount":92},[],{"trials":280,"activeCount":92},[],{"trials":282,"activeCount":209,"soonestReadout":62},[283],{"nctId":69,"briefTitle":70,"status":100,"phases":284,"primaryCompletion":62,"completion":62,"start":257,"enrollment":113,"conditions":285,"interventions":286},[82,83],[24,28,259,260,261,262,263,264,265,266,26],[71,268],{"trials":288,"activeCount":92},[],{"trials":290,"activeCount":92},[],{"intervention":78,"totalTrials":209,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":312,"NA":314},{"trials":294,"activeCount":92},[],{"trials":296,"activeCount":92},[],{"trials":298,"activeCount":92},[],{"trials":300,"activeCount":209,"soonestReadout":62},[301],{"nctId":76,"briefTitle":77,"status":100,"phases":302,"primaryCompletion":62,"completion":62,"start":102,"enrollment":113,"conditions":303,"interventions":310},[82,83],[24,149,304,264,28,305,306,177,307,308,309,26],"Thyroid Cancer, Papillary","Laryngeal Neoplasms","Carcinoma, Non-Small-Cell Lung","Multiple Myeloma","Erdheim-Chester Disease","Thyroid Carcinoma, Anaplastic",[78,311],"Cobimetinib",{"trials":313,"activeCount":92},[],{"trials":315,"activeCount":92},[],{"intervention":311,"totalTrials":209,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":330,"NA":332},{"trials":319,"activeCount":92},[],{"trials":321,"activeCount":92},[],{"trials":323,"activeCount":92},[],{"trials":325,"activeCount":209,"soonestReadout":62},[326],{"nctId":76,"briefTitle":77,"status":100,"phases":327,"primaryCompletion":62,"completion":62,"start":102,"enrollment":113,"conditions":328,"interventions":329},[82,83],[24,149,304,264,28,305,306,177,307,308,309,26],[78,311],{"trials":331,"activeCount":92},[],{"trials":333,"activeCount":92},[],{"intervention":335,"totalTrials":209,"cells":336},"Dabrafenib",{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":359,"NA":361},{"trials":338,"activeCount":92},[],{"trials":340,"activeCount":92},[],{"trials":342,"activeCount":92},[],{"trials":344,"activeCount":209,"soonestReadout":62},[345],{"nctId":346,"briefTitle":347,"status":348,"phases":349,"primaryCompletion":62,"completion":62,"start":350,"enrollment":113,"conditions":351,"interventions":357},"NCT07440290","DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With BRAF V600 Mutation-Positive Cancers.","NOT_YET_RECRUITING",[82,83],"2026-02",[24,115,116,117,118,352,353,354,22,308,355,264,28,305,356,177,307,309,26],"Gastrointestinal Cancer","Non-Melanoma Skin Cancer (NMSC)","Langerhans Cell Histiocytosis (LCH)","Thyroid Carcinoma, Papillary","Carcinoma, Non-Small Cell-Lung",[335,358],"Trametinib",{"trials":360,"activeCount":92},[],{"trials":362,"activeCount":92},[],{"intervention":358,"totalTrials":209,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":377,"NA":379},{"trials":366,"activeCount":92},[],{"trials":368,"activeCount":92},[],{"trials":370,"activeCount":92},[],{"trials":372,"activeCount":209,"soonestReadout":62},[373],{"nctId":346,"briefTitle":347,"status":348,"phases":374,"primaryCompletion":62,"completion":62,"start":350,"enrollment":113,"conditions":375,"interventions":376},[82,83],[24,115,116,117,118,352,353,354,22,308,355,264,28,305,356,177,307,309,26],[335,358],{"trials":378,"activeCount":92},[],{"trials":380,"activeCount":92},[],{"intervention":382,"totalTrials":209,"cells":383},"UCB4594",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":407,"PHASE4":409,"NA":411},{"trials":385,"activeCount":92},[],{"trials":387,"activeCount":92},[],{"trials":389,"activeCount":209,"soonestReadout":394},[390],{"nctId":391,"briefTitle":392,"status":100,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":406},"NCT06380816","A Phase I\u002FII Trial of UCB4594 in Participants With Advanced Cancer",[81,82],"2029-11","2024-07-09",167,[398,399,306,28,400,401,402,403,404,264,405],"Advanced Solid Tumours","Squamous Cell Carcinoma of Head and Neck","Triple Negative Breast Neoplasms","Carcinoma, Renal Cell (Clear Cell Only)","Esophageal Neoplasms","Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)","Uterine Cervical Neoplasms","Pancreatic Neoplasms",[382],{"trials":408,"activeCount":92},[],{"trials":410,"activeCount":92},[],{"trials":412,"activeCount":92},[],{"intervention":58,"totalTrials":209,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":416,"activeCount":92},[],{"trials":418,"activeCount":92},[],{"trials":420,"activeCount":209,"soonestReadout":57},[421],{"nctId":55,"briefTitle":56,"status":100,"phases":422,"primaryCompletion":57,"completion":423,"start":424,"enrollment":7,"conditions":425,"interventions":432},[81,82],"2029-12-21","2024-02-07",[426,427,428,429,430,431],"Lymphoma, Non-Hodgkin","Lymphoma, Large B-Cell, Diffuse","Lymphoma, Mantle-Cell","Lymphoma, Follicular","Lymphoma, B-Cell","Large B-cell Lymphoma",[58],{"trials":434,"activeCount":92},[],{"trials":436,"activeCount":92},[],{"trials":438,"activeCount":92},[],{"intervention":49,"totalTrials":209,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":464,"PHASE4":466,"NA":468},{"trials":442,"activeCount":92},[],{"trials":444,"activeCount":92},[],{"trials":446,"activeCount":209,"soonestReadout":48},[447],{"nctId":46,"briefTitle":47,"status":100,"phases":448,"primaryCompletion":48,"completion":48,"start":449,"enrollment":450,"conditions":451,"interventions":462},[81,82],"2023-07-13",150,[452,453,454,402,455,28,405,456,457,458,404,459,460,461],"Neoplasms","Prostatic Neoplasms, Castration-Resistant","Stomach Neoplasms","Head and Neck Neoplasms","Lung Neoplasms","Urinary Bladder Neoplasms","Mesothelioma, Malignant","Kidney Neoplasms","Sarcoma","Pheochromocytomas",[49,463],"HTL0039732 Capsules and atezolizumab",{"trials":465,"activeCount":92},[],{"trials":467,"activeCount":92},[],{"trials":469,"activeCount":92},[],{"intervention":463,"totalTrials":209,"cells":471},{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":473,"activeCount":92},[],{"trials":475,"activeCount":92},[],{"trials":477,"activeCount":209,"soonestReadout":48},[478],{"nctId":46,"briefTitle":47,"status":100,"phases":479,"primaryCompletion":48,"completion":48,"start":449,"enrollment":450,"conditions":480,"interventions":481},[81,82],[452,453,454,402,455,28,405,456,457,458,404,459,460,461],[49,463],{"trials":483,"activeCount":92},[],{"trials":485,"activeCount":92},[],{"trials":487,"activeCount":92},[],{"intervention":39,"totalTrials":209,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":491,"activeCount":92},[],{"trials":493,"activeCount":92},[],{"trials":495,"activeCount":209,"soonestReadout":38},[496],{"nctId":36,"briefTitle":37,"status":497,"phases":498,"primaryCompletion":38,"completion":38,"start":499,"enrollment":500,"conditions":501,"interventions":513},"ACTIVE_NOT_RECRUITING",[81,82],"2021-11-10",81,[502,503,504,505,506,507,201,508,149,509,510,33,511,512],"Bladder Cancer","Triple Negative Breast Cancer","Castration-resistant Prostate Cancer","Cervical Cancer","RAS Wild Type Colorectal Cancer","Endometrial Cancer","Hepatocellular Carcinoma (HCC)","Non-small Cell Lung Cancer (NSCLC)","Oesophageal Cancer","Pancreatic Cancer","Squamous Cell Cancer of the Head and Neck",[39,514],"HMBD-001 and enzalutamide",{"trials":516,"activeCount":92},[],{"trials":518,"activeCount":92},[],{"trials":520,"activeCount":92},[],{"intervention":514,"totalTrials":209,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":524,"activeCount":92},[],{"trials":526,"activeCount":92},[],{"trials":528,"activeCount":209,"soonestReadout":38},[529],{"nctId":36,"briefTitle":37,"status":497,"phases":530,"primaryCompletion":38,"completion":38,"start":499,"enrollment":500,"conditions":531,"interventions":532},[81,82],[502,503,504,505,506,507,201,508,149,509,510,33,511,512],[39,514],{"trials":534,"activeCount":92},[],{"trials":536,"activeCount":92},[],{"trials":538,"activeCount":92},[],{"intervention":53,"totalTrials":209,"cells":540},{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":542,"activeCount":92},[],{"trials":544,"activeCount":92},[],{"trials":546,"activeCount":209,"soonestReadout":48},[547],{"nctId":51,"briefTitle":52,"status":100,"phases":548,"primaryCompletion":48,"completion":48,"start":549,"enrollment":550,"conditions":551,"interventions":553},[81,82],"2022-01-19",188,[552],"Advanced Solid Tumors",[53,554],"Darolutamide",{"trials":556,"activeCount":92},[],{"trials":558,"activeCount":92},[],{"trials":560,"activeCount":92},[],{"intervention":554,"totalTrials":209,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":564,"activeCount":92},[],{"trials":566,"activeCount":92},[],{"trials":568,"activeCount":209,"soonestReadout":48},[569],{"nctId":51,"briefTitle":52,"status":100,"phases":570,"primaryCompletion":48,"completion":48,"start":549,"enrollment":550,"conditions":571,"interventions":572},[81,82],[552],[53,554],{"trials":574,"activeCount":92},[],{"trials":576,"activeCount":92},[],{"trials":578,"activeCount":92},[],{"intervention":44,"totalTrials":209,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":582,"activeCount":92},[],{"trials":584,"activeCount":209,"soonestReadout":43},[585],{"nctId":41,"briefTitle":42,"status":497,"phases":586,"primaryCompletion":43,"completion":43,"start":587,"enrollment":588,"conditions":589,"interventions":598},[81],"2017-06-21",69,[590,591,592,593,594,595,596,597],"A. Colorectal Cancer","B. High Grade Serous Ovarian Cancer","C. Non Small-cell Lung Cancer (squamous Cell Variant)","D. Squamous Carcinoma of the Oesophagus","E. Squamous Carcinoma of the Head and Neck (HPV Negative)","F. Urothelial Cancer","G. Breast Cancer (triple Negative Type)","H. Pancreatic Cancer",[44],{"trials":600,"activeCount":92},[],{"trials":602,"activeCount":92},[],{"trials":604,"activeCount":92},[],{"trials":606,"activeCount":92},[],{"intervention":608,"totalTrials":609,"cells":610},"vincristine sulfate",4,{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":630,"PHASE3":659,"PHASE4":673,"NA":675},{"trials":612,"activeCount":92},[],{"trials":614,"activeCount":92},[615],{"nctId":616,"briefTitle":617,"status":618,"phases":619,"primaryCompletion":620,"start":621,"enrollment":113,"conditions":622,"interventions":624},"NCT00562068","Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma","UNKNOWN",[81],"2009-05","2007-05",[16,623],"Small Intestine Cancer",[625,626,627,628,608,629],"alemtuzumab","cyclophosphamide","doxorubicin hydrochloride","prednisolone","polymerase chain reaction",{"trials":631,"activeCount":92},[632,647],{"nctId":633,"briefTitle":634,"status":618,"phases":635,"start":636,"enrollment":637,"conditions":638,"interventions":639},"NCT00669812","High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma",[82],"2008-02",60,[16,623],[640,626,641,627,642,643,644,645,646,628,608],"carmustine","cytarabine","epirubicin hydrochloride","etoposide","ifosfamide","melphalan","methotrexate",{"nctId":648,"briefTitle":649,"status":618,"phases":650,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":653,"interventions":654},"NCT00974792","Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma",[82],"2011-05","2006-01",[16],[655,656,626,641,627,657,644,658,646,608],"pegfilgrastim","rituximab","etoposide phosphate","leucovorin calcium",{"trials":660,"activeCount":92},[661],{"nctId":662,"briefTitle":663,"status":664,"phases":665,"completion":666,"start":667,"conditions":668,"interventions":670},"NCT00002476","Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer","COMPLETED",[83],"2010-01","1990-01",[669],"Head and Neck Cancer",[671,672,658,646,608],"bleomycin sulfate","fluorouracil",{"trials":674,"activeCount":92},[],{"trials":676,"activeCount":92},[],{"intervention":646,"totalTrials":13,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":693,"PHASE4":699,"NA":701},{"trials":680,"activeCount":92},[],{"trials":682,"activeCount":92},[],{"trials":684,"activeCount":92},[685,689],{"nctId":633,"briefTitle":634,"status":618,"phases":686,"start":636,"enrollment":637,"conditions":687,"interventions":688},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"nctId":648,"briefTitle":649,"status":618,"phases":690,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":691,"interventions":692},[82],[16],[655,656,626,641,627,657,644,658,646,608],{"trials":694,"activeCount":92},[695],{"nctId":662,"briefTitle":663,"status":664,"phases":696,"completion":666,"start":667,"conditions":697,"interventions":698},[83],[669],[671,672,658,646,608],{"trials":700,"activeCount":92},[],{"trials":702,"activeCount":92},[],{"intervention":704,"totalTrials":13,"cells":705},"capecitabine",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":742,"NA":744},{"trials":707,"activeCount":92},[],{"trials":709,"activeCount":92},[],{"trials":711,"activeCount":92},[],{"trials":713,"activeCount":92},[714,723,734],{"nctId":715,"briefTitle":716,"status":664,"phases":717,"completion":621,"start":718,"enrollment":719,"conditions":720,"interventions":721},"NCT00032175","Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[83],"2002-04",508,[511],[704,722],"gemcitabine hydrochloride",{"nctId":724,"briefTitle":725,"status":664,"phases":726,"primaryCompletion":727,"start":728,"enrollment":729,"conditions":730,"interventions":732},"NCT00749450","Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer",[83],"2017-11","2008-03",6088,[731],"Colorectal Cancer",[704,672,733],"oxaliplatin",{"nctId":735,"briefTitle":736,"status":664,"phases":737,"primaryCompletion":728,"start":738,"enrollment":739,"conditions":740,"interventions":741},"NCT00427713","Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer",[83],"2004-11",800,[731],[704,733],{"trials":743,"activeCount":92},[],{"trials":745,"activeCount":92},[],{"intervention":722,"totalTrials":88,"cells":747},{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":762,"PHASE3":764,"PHASE4":770,"NA":772},{"trials":749,"activeCount":92},[],{"trials":751,"activeCount":92},[752],{"nctId":753,"briefTitle":754,"status":664,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":760},"NCT01098344","MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery",[81],"2014-10","2010-04",44,[511],[761,722],"Notch signaling pathway inhibitor MK0752",{"trials":763,"activeCount":92},[],{"trials":765,"activeCount":92},[766],{"nctId":715,"briefTitle":716,"status":664,"phases":767,"completion":621,"start":718,"enrollment":719,"conditions":768,"interventions":769},[83],[511],[704,722],{"trials":771,"activeCount":92},[],{"trials":773,"activeCount":92},[],{"intervention":672,"totalTrials":88,"cells":775},{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":792,"NA":794},{"trials":777,"activeCount":92},[],{"trials":779,"activeCount":92},[],{"trials":781,"activeCount":92},[],{"trials":783,"activeCount":92},[784,788],{"nctId":724,"briefTitle":725,"status":664,"phases":785,"primaryCompletion":727,"start":728,"enrollment":729,"conditions":786,"interventions":787},[83],[731],[704,672,733],{"nctId":662,"briefTitle":663,"status":664,"phases":789,"completion":666,"start":667,"conditions":790,"interventions":791},[83],[669],[671,672,658,646,608],{"trials":793,"activeCount":92},[],{"trials":795,"activeCount":92},[],{"intervention":733,"totalTrials":88,"cells":797},{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":804,"PHASE4":814,"NA":816},{"trials":799,"activeCount":92},[],{"trials":801,"activeCount":92},[],{"trials":803,"activeCount":92},[],{"trials":805,"activeCount":92},[806,810],{"nctId":724,"briefTitle":725,"status":664,"phases":807,"primaryCompletion":727,"start":728,"enrollment":729,"conditions":808,"interventions":809},[83],[731],[704,672,733],{"nctId":735,"briefTitle":736,"status":664,"phases":811,"primaryCompletion":728,"start":738,"enrollment":739,"conditions":812,"interventions":813},[83],[731],[704,733],{"trials":815,"activeCount":92},[],{"trials":817,"activeCount":92},[],{"intervention":658,"totalTrials":88,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":830,"PHASE4":836,"NA":838},{"trials":821,"activeCount":92},[],{"trials":823,"activeCount":92},[],{"trials":825,"activeCount":92},[826],{"nctId":648,"briefTitle":649,"status":618,"phases":827,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":828,"interventions":829},[82],[16],[655,656,626,641,627,657,644,658,646,608],{"trials":831,"activeCount":92},[832],{"nctId":662,"briefTitle":663,"status":664,"phases":833,"completion":666,"start":667,"conditions":834,"interventions":835},[83],[669],[671,672,658,646,608],{"trials":837,"activeCount":92},[],{"trials":839,"activeCount":92},[],{"intervention":841,"totalTrials":209,"cells":842},"goserelin acetate",{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":859,"NA":861},{"trials":844,"activeCount":92},[],{"trials":846,"activeCount":92},[],{"trials":848,"activeCount":92},[],{"trials":850,"activeCount":92},[851],{"nctId":852,"briefTitle":853,"status":618,"phases":854,"start":855,"conditions":856,"interventions":857},"NCT00002460","Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer",[83],"1987-09",[19],[841,858],"tamoxifen citrate",{"trials":860,"activeCount":92},[],{"trials":862,"activeCount":92},[],{"intervention":858,"totalTrials":209,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":877,"NA":879},{"trials":866,"activeCount":92},[],{"trials":868,"activeCount":92},[],{"trials":870,"activeCount":92},[],{"trials":872,"activeCount":92},[873],{"nctId":852,"briefTitle":853,"status":618,"phases":874,"start":855,"conditions":875,"interventions":876},[83],[19],[841,858],{"trials":878,"activeCount":92},[],{"trials":880,"activeCount":92},[],{"intervention":882,"totalTrials":209,"cells":883},"cisplatin",{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":902,"NA":904},{"trials":885,"activeCount":92},[],{"trials":887,"activeCount":92},[],{"trials":889,"activeCount":92},[],{"trials":891,"activeCount":92},[892],{"nctId":893,"briefTitle":894,"status":618,"phases":895,"start":896,"conditions":897,"interventions":899},"NCT00004209","Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",[83],"1998-05",[898],"Lung Cancer",[882,900,901],"mitomycin C","vinblastine sulfate",{"trials":903,"activeCount":92},[],{"trials":905,"activeCount":92},[],{"intervention":900,"totalTrials":209,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":920,"NA":922},{"trials":909,"activeCount":92},[],{"trials":911,"activeCount":92},[],{"trials":913,"activeCount":92},[],{"trials":915,"activeCount":92},[916],{"nctId":893,"briefTitle":894,"status":618,"phases":917,"start":896,"conditions":918,"interventions":919},[83],[898],[882,900,901],{"trials":921,"activeCount":92},[],{"trials":923,"activeCount":92},[],{"intervention":901,"totalTrials":209,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":938,"NA":940},{"trials":927,"activeCount":92},[],{"trials":929,"activeCount":92},[],{"trials":931,"activeCount":92},[],{"trials":933,"activeCount":92},[934],{"nctId":893,"briefTitle":894,"status":618,"phases":935,"start":896,"conditions":936,"interventions":937},[83],[898],[882,900,901],{"trials":939,"activeCount":92},[],{"trials":941,"activeCount":92},[],{"intervention":671,"totalTrials":209,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":956,"NA":958},{"trials":945,"activeCount":92},[],{"trials":947,"activeCount":92},[],{"trials":949,"activeCount":92},[],{"trials":951,"activeCount":92},[952],{"nctId":662,"briefTitle":663,"status":664,"phases":953,"completion":666,"start":667,"conditions":954,"interventions":955},[83],[669],[671,672,658,646,608],{"trials":957,"activeCount":92},[],{"trials":959,"activeCount":92},[],{"intervention":961,"totalTrials":209,"cells":962},"ibandronate sodium",{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":969,"PHASE4":983,"NA":985},{"trials":964,"activeCount":92},[],{"trials":966,"activeCount":92},[],{"trials":968,"activeCount":92},[],{"trials":970,"activeCount":92},[971],{"nctId":972,"briefTitle":973,"status":664,"phases":974,"completion":975,"start":976,"enrollment":977,"conditions":978,"interventions":982},"NCT00082927","Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain",[83],"2011-07","2003-04",580,[979,980,981],"Metastatic Cancer","Pain","Prostate Cancer",[961],{"trials":984,"activeCount":92},[],{"trials":986,"activeCount":92},[],{"intervention":626,"totalTrials":988,"cells":989},8,{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":1022,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":991,"activeCount":92},[],{"trials":993,"activeCount":92},[994,998,1009],{"nctId":616,"briefTitle":617,"status":618,"phases":995,"primaryCompletion":620,"start":621,"enrollment":113,"conditions":996,"interventions":997},[81],[16,623],[625,626,627,628,608,629],{"nctId":999,"briefTitle":1000,"status":1001,"phases":1002,"primaryCompletion":757,"completion":757,"start":1003,"enrollment":9,"conditions":1004,"interventions":1005},"NCT01212887","Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer","TERMINATED",[81],"2007-08",[19,731,201,898,33,511,30],[1006,1007,626,1008],"MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes","aldesleukin","fludarabine phosphate",{"nctId":1010,"briefTitle":1011,"status":664,"phases":1012,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1018},"NCT02761915","A Phase I Trial of Anti-GD2 T-cells (1RG-CART)",[81],"2020-12-16","2016-02-29",17,[1017],"Relapsed or Refractory Neuroblastoma",[1019,1020,1021],"Cyclophosphamide","Fludarabine","1RG-CART",{"trials":1023,"activeCount":92},[1024,1028,1039,1050,1059],{"nctId":633,"briefTitle":634,"status":618,"phases":1025,"start":636,"enrollment":637,"conditions":1026,"interventions":1027},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"nctId":1029,"briefTitle":1030,"status":664,"phases":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT00337246","Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia",[82],"2011-03","2005-07",56,[1036],"Leukemia",[656,626,1008,1038],"mitoxantrone hydrochloride",{"nctId":1040,"briefTitle":1041,"status":618,"phases":1042,"primaryCompletion":1043,"start":1044,"enrollment":637,"conditions":1045,"interventions":1047},"NCT00959231","Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease",[82],"2012-08","2009-01",[1046],"Hematopoietic\u002FLymphoid Cancer",[626,1048,1008,1049],"cyclosporine","mycophenolate mofetil",{"nctId":1051,"briefTitle":1052,"status":618,"phases":1053,"primaryCompletion":1054,"start":652,"enrollment":1055,"conditions":1056,"interventions":1057},"NCT00958854","Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma",[82],"2012-03",37,[16],[626,1008,1058],"thalidomide",{"nctId":648,"briefTitle":649,"status":618,"phases":1060,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":1061,"interventions":1062},[82],[16],[655,656,626,641,627,657,644,658,646,608],{"trials":1064,"activeCount":92},[],{"trials":1066,"activeCount":92},[],{"trials":1068,"activeCount":92},[],{"intervention":1008,"totalTrials":1070,"cells":1071},5,{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1080,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1073,"activeCount":92},[],{"trials":1075,"activeCount":92},[1076],{"nctId":999,"briefTitle":1000,"status":1001,"phases":1077,"primaryCompletion":757,"completion":757,"start":1003,"enrollment":9,"conditions":1078,"interventions":1079},[81],[19,731,201,898,33,511,30],[1006,1007,626,1008],{"trials":1081,"activeCount":92},[1082,1086,1096,1100],{"nctId":1029,"briefTitle":1030,"status":664,"phases":1083,"completion":1032,"start":1033,"enrollment":1034,"conditions":1084,"interventions":1085},[82],[1036],[656,626,1008,1038],{"nctId":1087,"briefTitle":1088,"status":618,"phases":1089,"primaryCompletion":1090,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1094},"NCT00907036","Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma",[82],"2015-07","2009-07",49,[16],[625,1095,1048,1008,645],"donor lymphocytes",{"nctId":1040,"briefTitle":1041,"status":618,"phases":1097,"primaryCompletion":1043,"start":1044,"enrollment":637,"conditions":1098,"interventions":1099},[82],[1046],[626,1048,1008,1049],{"nctId":1051,"briefTitle":1052,"status":618,"phases":1101,"primaryCompletion":1054,"start":652,"enrollment":1055,"conditions":1102,"interventions":1103},[82],[16],[626,1008,1058],{"trials":1105,"activeCount":92},[],{"trials":1107,"activeCount":92},[],{"trials":1109,"activeCount":92},[],{"intervention":641,"totalTrials":609,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1143,"PHASE4":1145,"NA":1147},{"trials":1113,"activeCount":92},[],{"trials":1115,"activeCount":92},[],{"trials":1117,"activeCount":92},[1118,1122,1130,1139],{"nctId":633,"briefTitle":634,"status":618,"phases":1119,"start":636,"enrollment":637,"conditions":1120,"interventions":1121},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"nctId":1123,"briefTitle":1124,"status":618,"phases":1125,"primaryCompletion":1126,"start":1091,"enrollment":1127,"conditions":1128,"interventions":1129},"NCT00908180","Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma",[82],"2014-07",47,[16],[625,1095,640,1048,641,643,645],{"nctId":1131,"briefTitle":1132,"status":618,"phases":1133,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1138},"NCT00720447","Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma",[82],"2010-11","2008-11",25,[16],[625,1095,640,641,643,645],{"nctId":648,"briefTitle":649,"status":618,"phases":1140,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":1141,"interventions":1142},[82],[16],[655,656,626,641,627,657,644,658,646,608],{"trials":1144,"activeCount":92},[],{"trials":1146,"activeCount":92},[],{"trials":1148,"activeCount":92},[],{"intervention":643,"totalTrials":609,"cells":1150},{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1178,"PHASE4":1180,"NA":1182},{"trials":1152,"activeCount":92},[],{"trials":1154,"activeCount":92},[],{"trials":1156,"activeCount":92},[1157,1161,1165,1169],{"nctId":633,"briefTitle":634,"status":618,"phases":1158,"start":636,"enrollment":637,"conditions":1159,"interventions":1160},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"nctId":1123,"briefTitle":1124,"status":618,"phases":1162,"primaryCompletion":1126,"start":1091,"enrollment":1127,"conditions":1163,"interventions":1164},[82],[16],[625,1095,640,1048,641,643,645],{"nctId":1131,"briefTitle":1132,"status":618,"phases":1166,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":1167,"interventions":1168},[82],[16],[625,1095,640,641,643,645],{"nctId":1170,"briefTitle":1171,"status":1172,"phases":1173,"start":1044,"enrollment":92,"conditions":1174,"interventions":1175},"NCT00829205","Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment","WITHDRAWN",[81,82],[16],[1176,656,1177,643,644],"filgrastim","carboplatin",{"trials":1179,"activeCount":92},[],{"trials":1181,"activeCount":92},[],{"trials":1183,"activeCount":92},[],{"intervention":645,"totalTrials":609,"cells":1185},{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1187,"activeCount":92},[],{"trials":1189,"activeCount":92},[],{"trials":1191,"activeCount":92},[1192,1196,1200,1204],{"nctId":633,"briefTitle":634,"status":618,"phases":1193,"start":636,"enrollment":637,"conditions":1194,"interventions":1195},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"nctId":1123,"briefTitle":1124,"status":618,"phases":1197,"primaryCompletion":1126,"start":1091,"enrollment":1127,"conditions":1198,"interventions":1199},[82],[16],[625,1095,640,1048,641,643,645],{"nctId":1131,"briefTitle":1132,"status":618,"phases":1201,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":1202,"interventions":1203},[82],[16],[625,1095,640,641,643,645],{"nctId":1087,"briefTitle":1088,"status":618,"phases":1205,"primaryCompletion":1090,"start":1091,"enrollment":1092,"conditions":1206,"interventions":1207},[82],[16],[625,1095,1048,1008,645],{"trials":1209,"activeCount":92},[],{"trials":1211,"activeCount":92},[],{"trials":1213,"activeCount":92},[],{"intervention":625,"totalTrials":609,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1224,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1217,"activeCount":92},[],{"trials":1219,"activeCount":92},[1220],{"nctId":616,"briefTitle":617,"status":618,"phases":1221,"primaryCompletion":620,"start":621,"enrollment":113,"conditions":1222,"interventions":1223},[81],[16,623],[625,626,627,628,608,629],{"trials":1225,"activeCount":92},[1226,1230,1234],{"nctId":1123,"briefTitle":1124,"status":618,"phases":1227,"primaryCompletion":1126,"start":1091,"enrollment":1127,"conditions":1228,"interventions":1229},[82],[16],[625,1095,640,1048,641,643,645],{"nctId":1131,"briefTitle":1132,"status":618,"phases":1231,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":1232,"interventions":1233},[82],[16],[625,1095,640,641,643,645],{"nctId":1087,"briefTitle":1088,"status":618,"phases":1235,"primaryCompletion":1090,"start":1091,"enrollment":1092,"conditions":1236,"interventions":1237},[82],[16],[625,1095,1048,1008,645],{"trials":1239,"activeCount":92},[],{"trials":1241,"activeCount":92},[],{"trials":1243,"activeCount":92},[],{"intervention":640,"totalTrials":13,"cells":1245},{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1264,"PHASE4":1266,"NA":1268},{"trials":1247,"activeCount":92},[],{"trials":1249,"activeCount":92},[],{"trials":1251,"activeCount":92},[1252,1256,1260],{"nctId":633,"briefTitle":634,"status":618,"phases":1253,"start":636,"enrollment":637,"conditions":1254,"interventions":1255},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"nctId":1123,"briefTitle":1124,"status":618,"phases":1257,"primaryCompletion":1126,"start":1091,"enrollment":1127,"conditions":1258,"interventions":1259},[82],[16],[625,1095,640,1048,641,643,645],{"nctId":1131,"briefTitle":1132,"status":618,"phases":1261,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":1262,"interventions":1263},[82],[16],[625,1095,640,641,643,645],{"trials":1265,"activeCount":92},[],{"trials":1267,"activeCount":92},[],{"trials":1269,"activeCount":92},[],{"intervention":627,"totalTrials":13,"cells":1271},{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1280,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1273,"activeCount":92},[],{"trials":1275,"activeCount":92},[1276],{"nctId":616,"briefTitle":617,"status":618,"phases":1277,"primaryCompletion":620,"start":621,"enrollment":113,"conditions":1278,"interventions":1279},[81],[16,623],[625,626,627,628,608,629],{"trials":1281,"activeCount":92},[1282,1286],{"nctId":633,"briefTitle":634,"status":618,"phases":1283,"start":636,"enrollment":637,"conditions":1284,"interventions":1285},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"nctId":648,"briefTitle":649,"status":618,"phases":1287,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":1288,"interventions":1289},[82],[16],[655,656,626,641,627,657,644,658,646,608],{"trials":1291,"activeCount":92},[],{"trials":1293,"activeCount":92},[],{"trials":1295,"activeCount":92},[],{"intervention":644,"totalTrials":13,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1316,"PHASE4":1318,"NA":1320},{"trials":1299,"activeCount":92},[],{"trials":1301,"activeCount":92},[],{"trials":1303,"activeCount":92},[1304,1308,1312],{"nctId":633,"briefTitle":634,"status":618,"phases":1305,"start":636,"enrollment":637,"conditions":1306,"interventions":1307},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"nctId":1170,"briefTitle":1171,"status":1172,"phases":1309,"start":1044,"enrollment":92,"conditions":1310,"interventions":1311},[81,82],[16],[1176,656,1177,643,644],{"nctId":648,"briefTitle":649,"status":618,"phases":1313,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":1314,"interventions":1315},[82],[16],[655,656,626,641,627,657,644,658,646,608],{"trials":1317,"activeCount":92},[],{"trials":1319,"activeCount":92},[],{"trials":1321,"activeCount":92},[],{"intervention":1058,"totalTrials":13,"cells":1323},{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1351,"PHASE4":1353,"NA":1355},{"trials":1325,"activeCount":92},[],{"trials":1327,"activeCount":92},[],{"trials":1329,"activeCount":92},[1330,1340,1347],{"nctId":1331,"briefTitle":1332,"status":618,"phases":1333,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1338},"NCT00027664","Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer",[82],"2001-02",90,[1337],"Kidney Cancer",[1339,1058],"recombinant interferon alfa",{"nctId":1341,"briefTitle":1342,"status":664,"phases":1343,"start":1344,"enrollment":113,"conditions":1345,"interventions":1346},"NCT00004876","Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer",[82],"1999-08",[33],[1177,1058],{"nctId":1051,"briefTitle":1052,"status":618,"phases":1348,"primaryCompletion":1054,"start":652,"enrollment":1055,"conditions":1349,"interventions":1350},[82],[16],[626,1008,1058],{"trials":1352,"activeCount":92},[],{"trials":1354,"activeCount":92},[],{"trials":1356,"activeCount":92},[],{"intervention":1095,"totalTrials":13,"cells":1358},{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1360,"activeCount":92},[],{"trials":1362,"activeCount":92},[],{"trials":1364,"activeCount":92},[1365,1369,1373],{"nctId":1123,"briefTitle":1124,"status":618,"phases":1366,"primaryCompletion":1126,"start":1091,"enrollment":1127,"conditions":1367,"interventions":1368},[82],[16],[625,1095,640,1048,641,643,645],{"nctId":1131,"briefTitle":1132,"status":618,"phases":1370,"primaryCompletion":1134,"start":1135,"enrollment":1136,"conditions":1371,"interventions":1372},[82],[16],[625,1095,640,641,643,645],{"nctId":1087,"briefTitle":1088,"status":618,"phases":1374,"primaryCompletion":1090,"start":1091,"enrollment":1092,"conditions":1375,"interventions":1376},[82],[16],[625,1095,1048,1008,645],{"trials":1378,"activeCount":92},[],{"trials":1380,"activeCount":92},[],{"trials":1382,"activeCount":92},[],{"intervention":1048,"totalTrials":13,"cells":1384},{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1386,"activeCount":92},[],{"trials":1388,"activeCount":92},[],{"trials":1390,"activeCount":92},[1391,1395,1399],{"nctId":1123,"briefTitle":1124,"status":618,"phases":1392,"primaryCompletion":1126,"start":1091,"enrollment":1127,"conditions":1393,"interventions":1394},[82],[16],[625,1095,640,1048,641,643,645],{"nctId":1087,"briefTitle":1088,"status":618,"phases":1396,"primaryCompletion":1090,"start":1091,"enrollment":1092,"conditions":1397,"interventions":1398},[82],[16],[625,1095,1048,1008,645],{"nctId":1040,"briefTitle":1041,"status":618,"phases":1400,"primaryCompletion":1043,"start":1044,"enrollment":637,"conditions":1401,"interventions":1402},[82],[1046],[626,1048,1008,1049],{"trials":1404,"activeCount":92},[],{"trials":1406,"activeCount":92},[],{"trials":1408,"activeCount":92},[],{"intervention":1410,"totalTrials":13,"cells":1411},"protein expression analysis",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1428,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1413,"activeCount":92},[],{"trials":1415,"activeCount":92},[1416],{"nctId":1417,"briefTitle":1418,"status":664,"phases":1419,"primaryCompletion":1420,"completion":1420,"start":975,"enrollment":1421,"conditions":1422,"interventions":1424},"NCT01390571","Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma",[81],"2017-06-20",34,[1423],"Brain and Central Nervous System Tumors",[1425,1426,1427,1410],"olaparib","temozolomide","gene expression analysis",{"trials":1429,"activeCount":92},[1430,1443],{"nctId":1431,"briefTitle":1432,"status":664,"phases":1433,"primaryCompletion":1434,"completion":1434,"start":1435,"enrollment":1436,"conditions":1437,"interventions":1440},"NCT00664781","Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer",[82],"2015-01","2007-12",78,[1438,1439,19,33],"brca1 Mutation Carrier","brca2 Mutation Carrier",[1441,1410,1442],"rucaparib","western blotting",{"nctId":1444,"briefTitle":1445,"status":1001,"phases":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":1450,"interventions":1451},"NCT00674557","Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer",[82],"2009-03","2008-06",111,[19],[1452,1453,1410,1454],"SOD1 inhibitor ATN-224","exemestane","proteomic profiling",{"trials":1456,"activeCount":92},[],{"trials":1458,"activeCount":92},[],{"trials":1460,"activeCount":92},[],{"intervention":656,"totalTrials":13,"cells":1462},{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1481,"PHASE4":1483,"NA":1485},{"trials":1464,"activeCount":92},[],{"trials":1466,"activeCount":92},[],{"trials":1468,"activeCount":92},[1469,1473,1477],{"nctId":1029,"briefTitle":1030,"status":664,"phases":1470,"completion":1032,"start":1033,"enrollment":1034,"conditions":1471,"interventions":1472},[82],[1036],[656,626,1008,1038],{"nctId":1170,"briefTitle":1171,"status":1172,"phases":1474,"start":1044,"enrollment":92,"conditions":1475,"interventions":1476},[81,82],[16],[1176,656,1177,643,644],{"nctId":648,"briefTitle":649,"status":618,"phases":1478,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":1479,"interventions":1480},[82],[16],[655,656,626,641,627,657,644,658,646,608],{"trials":1482,"activeCount":92},[],{"trials":1484,"activeCount":92},[],{"trials":1486,"activeCount":92},[],{"intervention":1177,"totalTrials":13,"cells":1488},{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1490,"activeCount":92},[],{"trials":1492,"activeCount":92},[],{"trials":1494,"activeCount":92},[1495,1499,1503],{"nctId":1341,"briefTitle":1342,"status":664,"phases":1496,"start":1344,"enrollment":113,"conditions":1497,"interventions":1498},[82],[33],[1177,1058],{"nctId":1170,"briefTitle":1171,"status":1172,"phases":1500,"start":1044,"enrollment":92,"conditions":1501,"interventions":1502},[81,82],[16],[1176,656,1177,643,644],{"nctId":1504,"briefTitle":1505,"status":1001,"phases":1506,"primaryCompletion":1507,"completion":1134,"start":1508,"enrollment":1509,"conditions":1510,"interventions":1513},"NCT00748527","Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",[82],"2009-12","2007-07",134,[1511,33,1512],"Fallopian Tube Cancer","Peritoneal Cavity Cancer",[1177,1514],"decitabine",{"trials":1516,"activeCount":92},[],{"trials":1518,"activeCount":92},[],{"trials":1520,"activeCount":92},[],{"intervention":628,"totalTrials":88,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1531,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1524,"activeCount":92},[],{"trials":1526,"activeCount":92},[1527],{"nctId":616,"briefTitle":617,"status":618,"phases":1528,"primaryCompletion":620,"start":621,"enrollment":113,"conditions":1529,"interventions":1530},[81],[16,623],[625,626,627,628,608,629],{"trials":1532,"activeCount":92},[1533],{"nctId":633,"briefTitle":634,"status":618,"phases":1534,"start":636,"enrollment":637,"conditions":1535,"interventions":1536},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"trials":1538,"activeCount":92},[],{"trials":1540,"activeCount":92},[],{"trials":1542,"activeCount":92},[],{"intervention":1544,"totalTrials":88,"cells":1545},"tanespimycin",{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1558,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1547,"activeCount":92},[],{"trials":1549,"activeCount":92},[1550],{"nctId":1551,"briefTitle":1552,"status":664,"phases":1553,"completion":1554,"start":1555,"conditions":1556,"interventions":1557},"NCT00003969","Geldanamycin Analogue in Treating Patients With Advanced Cancer",[81],"2007-01","1998-08",[30],[1544],{"trials":1559,"activeCount":92},[1560],{"nctId":1561,"briefTitle":1562,"status":664,"phases":1563,"primaryCompletion":1134,"completion":1134,"start":1564,"enrollment":1136,"conditions":1565,"interventions":1567},"NCT00104897","17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma",[82],"2005-03",[1566],"Melanoma (Skin)",[1544],{"trials":1569,"activeCount":92},[],{"trials":1571,"activeCount":92},[],{"trials":1573,"activeCount":92},[],{"intervention":1575,"totalTrials":209,"cells":1576},"[124I]meta-Iodobenzylguanidine",{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1593,"PHASE4":1595,"NA":1597},{"trials":1578,"activeCount":92},[],{"trials":1580,"activeCount":92},[],{"trials":1582,"activeCount":92},[1583],{"nctId":1584,"briefTitle":1585,"status":664,"phases":1586,"primaryCompletion":1587,"completion":1587,"start":1588,"enrollment":1589,"conditions":1590,"interventions":1592},"NCT02043899","A Phase I\u002FII Study of [124I]mIBG PET\u002FCT in Neuroblastoma",[81,82],"2020-10-15","2014-02",36,[1591],"Metastatic Neuroblastoma",[1575],{"trials":1594,"activeCount":92},[],{"trials":1596,"activeCount":92},[],{"trials":1598,"activeCount":92},[],{"intervention":642,"totalTrials":209,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1611,"PHASE4":1613,"NA":1615},{"trials":1602,"activeCount":92},[],{"trials":1604,"activeCount":92},[],{"trials":1606,"activeCount":92},[1607],{"nctId":633,"briefTitle":634,"status":618,"phases":1608,"start":636,"enrollment":637,"conditions":1609,"interventions":1610},[82],[16,623],[640,626,641,627,642,643,644,645,646,628,608],{"trials":1612,"activeCount":92},[],{"trials":1614,"activeCount":92},[],{"trials":1616,"activeCount":92},[],{"intervention":1339,"totalTrials":209,"cells":1618},{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1623,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1620,"activeCount":92},[],{"trials":1622,"activeCount":92},[],{"trials":1624,"activeCount":92},[1625],{"nctId":1331,"briefTitle":1332,"status":618,"phases":1626,"start":1334,"enrollment":1335,"conditions":1627,"interventions":1628},[82],[1337],[1339,1058],{"trials":1630,"activeCount":92},[],{"trials":1632,"activeCount":92},[],{"trials":1634,"activeCount":92},[],{"intervention":1636,"totalTrials":209,"cells":1637},"BT1718",{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1642,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1639,"activeCount":92},[],{"trials":1641,"activeCount":92},[],{"trials":1643,"activeCount":92},[1644],{"nctId":1645,"briefTitle":1646,"status":664,"phases":1647,"primaryCompletion":1648,"completion":1648,"start":1649,"enrollment":1650,"conditions":1651,"interventions":1654},"NCT03486730","BT1718 in Patients with Advanced Solid Tumours.",[81,82],"2023-11-20","2018-01-24",72,[398,1652,1653,510],"Non-Small Cell Lung Cancer","Non-Small Cell Lung Sarcoma",[1636],{"trials":1656,"activeCount":92},[],{"trials":1658,"activeCount":92},[],{"trials":1660,"activeCount":92},[],{"intervention":1441,"totalTrials":209,"cells":1662},{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1673,"PHASE4":1675,"NA":1677},{"trials":1664,"activeCount":92},[],{"trials":1666,"activeCount":92},[],{"trials":1668,"activeCount":92},[1669],{"nctId":1431,"briefTitle":1432,"status":664,"phases":1670,"primaryCompletion":1434,"completion":1434,"start":1435,"enrollment":1436,"conditions":1671,"interventions":1672},[82],[1438,1439,19,33],[1441,1410,1442],{"trials":1674,"activeCount":92},[],{"trials":1676,"activeCount":92},[],{"trials":1678,"activeCount":92},[],{"intervention":1442,"totalTrials":209,"cells":1680},{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1685,"PHASE3":1691,"PHASE4":1693,"NA":1695},{"trials":1682,"activeCount":92},[],{"trials":1684,"activeCount":92},[],{"trials":1686,"activeCount":92},[1687],{"nctId":1431,"briefTitle":1432,"status":664,"phases":1688,"primaryCompletion":1434,"completion":1434,"start":1435,"enrollment":1436,"conditions":1689,"interventions":1690},[82],[1438,1439,19,33],[1441,1410,1442],{"trials":1692,"activeCount":92},[],{"trials":1694,"activeCount":92},[],{"trials":1696,"activeCount":92},[],{"intervention":1698,"totalTrials":209,"cells":1699},"AMG 319 hydrate",{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1704,"PHASE3":1717,"PHASE4":1719,"NA":1721},{"trials":1701,"activeCount":92},[],{"trials":1703,"activeCount":92},[],{"trials":1705,"activeCount":92},[1706],{"nctId":1707,"briefTitle":1708,"status":1001,"phases":1709,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":1712,"conditions":1713,"interventions":1716},"NCT02540928","AMG 319 in HPV Positive and Negative HNSCC",[82],"2018-05-03","2015-10",35,[1714,1715],"Human Papillomavirus (HPV)","Positive or Negative Head and Neck Squamous Cell Carcinoma (HNSCC) of the Hypopharynx, Oropharynx, Oral Cavity, Supraglottis or Larynx",[1698],{"trials":1718,"activeCount":92},[],{"trials":1720,"activeCount":92},[],{"trials":1722,"activeCount":92},[],{"intervention":1724,"totalTrials":209,"cells":1725},"ChAdOx1-MAGEA3-NYESO",{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1749,"PHASE4":1751,"NA":1753},{"trials":1727,"activeCount":92},[],{"trials":1729,"activeCount":92},[],{"trials":1731,"activeCount":92},[1732],{"nctId":1733,"briefTitle":1734,"status":1735,"phases":1736,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":10,"conditions":1740,"interventions":1742},"NCT04908111","A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1","SUSPENDED",[81,82],"2024-09-18","2026-10-16","2021-10-15",[509,1741],"Squamous Oesophageal Cancer",[1724,1743,1744,1745,1746,1747,1748,1746,1747],"MVA-MAGEA3","Standard of care treatment","MVA-NYESO","Biological\u002FVaccine: ChAdOx1-MAGEA3-NYESO","Biological\u002FVaccine: MVA-MAGEA3","Biological\u002FVaccine: MVA-NYESO",{"trials":1750,"activeCount":92},[],{"trials":1752,"activeCount":92},[],{"trials":1754,"activeCount":92},[],{"intervention":1743,"totalTrials":209,"cells":1756},{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1758,"activeCount":92},[],{"trials":1760,"activeCount":92},[],{"trials":1762,"activeCount":92},[1763],{"nctId":1733,"briefTitle":1734,"status":1735,"phases":1764,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":10,"conditions":1765,"interventions":1766},[81,82],[509,1741],[1724,1743,1744,1745,1746,1747,1748,1746,1747],{"trials":1768,"activeCount":92},[],{"trials":1770,"activeCount":92},[],{"trials":1772,"activeCount":92},[],{"intervention":1744,"totalTrials":209,"cells":1774},{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1785,"PHASE4":1787,"NA":1789},{"trials":1776,"activeCount":92},[],{"trials":1778,"activeCount":92},[],{"trials":1780,"activeCount":92},[1781],{"nctId":1733,"briefTitle":1734,"status":1735,"phases":1782,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":10,"conditions":1783,"interventions":1784},[81,82],[509,1741],[1724,1743,1744,1745,1746,1747,1748,1746,1747],{"trials":1786,"activeCount":92},[],{"trials":1788,"activeCount":92},[],{"trials":1790,"activeCount":92},[],{"intervention":1745,"totalTrials":209,"cells":1792},{"EARLY_PHASE1":1793,"PHASE1":1795,"PHASE2":1797,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1794,"activeCount":92},[],{"trials":1796,"activeCount":92},[],{"trials":1798,"activeCount":92},[1799],{"nctId":1733,"briefTitle":1734,"status":1735,"phases":1800,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":10,"conditions":1801,"interventions":1802},[81,82],[509,1741],[1724,1743,1744,1745,1746,1747,1748,1746,1747],{"trials":1804,"activeCount":92},[],{"trials":1806,"activeCount":92},[],{"trials":1808,"activeCount":92},[],{"intervention":1746,"totalTrials":209,"cells":1810},{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1812,"activeCount":92},[],{"trials":1814,"activeCount":92},[],{"trials":1816,"activeCount":92},[1817],{"nctId":1733,"briefTitle":1734,"status":1735,"phases":1818,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":10,"conditions":1819,"interventions":1820},[81,82],[509,1741],[1724,1743,1744,1745,1746,1747,1748,1746,1747],{"trials":1822,"activeCount":92},[],{"trials":1824,"activeCount":92},[],{"trials":1826,"activeCount":92},[],{"intervention":1747,"totalTrials":209,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1830,"activeCount":92},[],{"trials":1832,"activeCount":92},[],{"trials":1834,"activeCount":92},[1835],{"nctId":1733,"briefTitle":1734,"status":1735,"phases":1836,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":10,"conditions":1837,"interventions":1838},[81,82],[509,1741],[1724,1743,1744,1745,1746,1747,1748,1746,1747],{"trials":1840,"activeCount":92},[],{"trials":1842,"activeCount":92},[],{"trials":1844,"activeCount":92},[],{"intervention":1748,"totalTrials":209,"cells":1846},{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1848,"activeCount":92},[],{"trials":1850,"activeCount":92},[],{"trials":1852,"activeCount":92},[1853],{"nctId":1733,"briefTitle":1734,"status":1735,"phases":1854,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":10,"conditions":1855,"interventions":1856},[81,82],[509,1741],[1724,1743,1744,1745,1746,1747,1748,1746,1747],{"trials":1858,"activeCount":92},[],{"trials":1860,"activeCount":92},[],{"trials":1862,"activeCount":92},[],{"intervention":1038,"totalTrials":209,"cells":1864},{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1866,"activeCount":92},[],{"trials":1868,"activeCount":92},[],{"trials":1870,"activeCount":92},[1871],{"nctId":1029,"briefTitle":1030,"status":664,"phases":1872,"completion":1032,"start":1033,"enrollment":1034,"conditions":1873,"interventions":1874},[82],[1036],[656,626,1008,1038],{"trials":1876,"activeCount":92},[],{"trials":1878,"activeCount":92},[],{"trials":1880,"activeCount":92},[],{"intervention":1882,"totalTrials":209,"cells":1883},"abiraterone acetate",{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1899,"PHASE4":1901,"NA":1903},{"trials":1885,"activeCount":92},[],{"trials":1887,"activeCount":92},[],{"trials":1889,"activeCount":92},[1890],{"nctId":1891,"briefTitle":1892,"status":664,"phases":1893,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":1897,"interventions":1898},"NCT00755885","Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer",[81,82],"2016-06-04","2008-10",77,[19],[1882],{"trials":1900,"activeCount":92},[],{"trials":1902,"activeCount":92},[],{"trials":1904,"activeCount":92},[],{"intervention":1049,"totalTrials":209,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1917,"PHASE4":1919,"NA":1921},{"trials":1908,"activeCount":92},[],{"trials":1910,"activeCount":92},[],{"trials":1912,"activeCount":92},[1913],{"nctId":1040,"briefTitle":1041,"status":618,"phases":1914,"primaryCompletion":1043,"start":1044,"enrollment":637,"conditions":1915,"interventions":1916},[82],[1046],[626,1048,1008,1049],{"trials":1918,"activeCount":92},[],{"trials":1920,"activeCount":92},[],{"trials":1922,"activeCount":92},[],{"intervention":1176,"totalTrials":209,"cells":1924},{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1926,"activeCount":92},[],{"trials":1928,"activeCount":92},[],{"trials":1930,"activeCount":92},[1931],{"nctId":1170,"briefTitle":1171,"status":1172,"phases":1932,"start":1044,"enrollment":92,"conditions":1933,"interventions":1934},[81,82],[16],[1176,656,1177,643,644],{"trials":1936,"activeCount":92},[],{"trials":1938,"activeCount":92},[],{"trials":1940,"activeCount":92},[],{"intervention":1942,"totalTrials":209,"cells":1943},"Camostat",{"EARLY_PHASE1":1944,"PHASE1":1946,"PHASE2":1948,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1945,"activeCount":92},[],{"trials":1947,"activeCount":92},[],{"trials":1949,"activeCount":92},[1950],{"nctId":1951,"briefTitle":1952,"status":1001,"phases":1953,"primaryCompletion":1954,"completion":1955,"start":1956,"enrollment":1421,"conditions":1957,"interventions":1959},"NCT04455815","A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)",[82],"2021-11-29","2022-03-03","2020-09-23",[1958],"COVID-19 Infection",[1942],{"trials":1961,"activeCount":92},[],{"trials":1963,"activeCount":92},[],{"trials":1965,"activeCount":92},[],{"intervention":1452,"totalTrials":209,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1969,"activeCount":92},[],{"trials":1971,"activeCount":92},[],{"trials":1973,"activeCount":92},[1974],{"nctId":1444,"briefTitle":1445,"status":1001,"phases":1975,"completion":1447,"start":1448,"enrollment":1449,"conditions":1976,"interventions":1977},[82],[19],[1452,1453,1410,1454],{"trials":1979,"activeCount":92},[],{"trials":1981,"activeCount":92},[],{"trials":1983,"activeCount":92},[],{"intervention":1453,"totalTrials":209,"cells":1985},{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1987,"activeCount":92},[],{"trials":1989,"activeCount":92},[],{"trials":1991,"activeCount":92},[1992],{"nctId":1444,"briefTitle":1445,"status":1001,"phases":1993,"completion":1447,"start":1448,"enrollment":1449,"conditions":1994,"interventions":1995},[82],[19],[1452,1453,1410,1454],{"trials":1997,"activeCount":92},[],{"trials":1999,"activeCount":92},[],{"trials":2001,"activeCount":92},[],{"intervention":1454,"totalTrials":209,"cells":2003},{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2008,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2005,"activeCount":92},[],{"trials":2007,"activeCount":92},[],{"trials":2009,"activeCount":92},[2010],{"nctId":1444,"briefTitle":1445,"status":1001,"phases":2011,"completion":1447,"start":1448,"enrollment":1449,"conditions":2012,"interventions":2013},[82],[19],[1452,1453,1410,1454],{"trials":2015,"activeCount":92},[],{"trials":2017,"activeCount":92},[],{"trials":2019,"activeCount":92},[],{"intervention":1514,"totalTrials":209,"cells":2021},{"EARLY_PHASE1":2022,"PHASE1":2024,"PHASE2":2026,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":2023,"activeCount":92},[],{"trials":2025,"activeCount":92},[],{"trials":2027,"activeCount":92},[2028],{"nctId":1504,"briefTitle":1505,"status":1001,"phases":2029,"primaryCompletion":1507,"completion":1134,"start":1508,"enrollment":1509,"conditions":2030,"interventions":2031},[82],[1511,33,1512],[1177,1514],{"trials":2033,"activeCount":92},[],{"trials":2035,"activeCount":92},[],{"trials":2037,"activeCount":92},[],{"intervention":655,"totalTrials":209,"cells":2039},{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2044,"PHASE3":2050,"PHASE4":2052,"NA":2054},{"trials":2041,"activeCount":92},[],{"trials":2043,"activeCount":92},[],{"trials":2045,"activeCount":92},[2046],{"nctId":648,"briefTitle":649,"status":618,"phases":2047,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":2048,"interventions":2049},[82],[16],[655,656,626,641,627,657,644,658,646,608],{"trials":2051,"activeCount":92},[],{"trials":2053,"activeCount":92},[],{"trials":2055,"activeCount":92},[],{"intervention":657,"totalTrials":209,"cells":2057},{"EARLY_PHASE1":2058,"PHASE1":2060,"PHASE2":2062,"PHASE3":2068,"PHASE4":2070,"NA":2072},{"trials":2059,"activeCount":92},[],{"trials":2061,"activeCount":92},[],{"trials":2063,"activeCount":92},[2064],{"nctId":648,"briefTitle":649,"status":618,"phases":2065,"primaryCompletion":651,"start":652,"enrollment":450,"conditions":2066,"interventions":2067},[82],[16],[655,656,626,641,627,657,644,658,646,608],{"trials":2069,"activeCount":92},[],{"trials":2071,"activeCount":92},[],{"trials":2073,"activeCount":92},[],{"intervention":2075,"totalTrials":209,"cells":2076},"TroVax",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2092,"PHASE4":2094,"NA":2096},{"trials":2078,"activeCount":92},[],{"trials":2080,"activeCount":92},[],{"trials":2082,"activeCount":92},[2083],{"nctId":2084,"briefTitle":2085,"status":664,"phases":2086,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2091},"NCT00259844","Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed",[82],"2006-12","2004-06",20,[28],[2075],{"trials":2093,"activeCount":92},[],{"trials":2095,"activeCount":92},[],{"trials":2097,"activeCount":92},[],{"intervention":2099,"totalTrials":209,"cells":2100},"BI-1206 single agent dose escalation phase",{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2121,"PHASE4":2123,"NA":2125},{"trials":2102,"activeCount":92},[],{"trials":2104,"activeCount":92},[],{"trials":2106,"activeCount":92},[2107],{"nctId":2108,"briefTitle":2109,"status":664,"phases":2110,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":9,"conditions":2113,"interventions":2117},"NCT02933320","BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia",[81,82],"2020-03-19","2016-10-27",[2114,2115,2116],"B-cell Lymphoma","Chronic Lymphocytic Leukaemia","Waldenström Macroglobulinemia",[2099,2118,2119,2120],"Combination of BI-1206 with rituximab escalation phase","BI-1206 single agent expansion phase","Combination of BI-1206 with rituximab expansion phase",{"trials":2122,"activeCount":92},[],{"trials":2124,"activeCount":92},[],{"trials":2126,"activeCount":92},[],{"intervention":2118,"totalTrials":209,"cells":2128},{"EARLY_PHASE1":2129,"PHASE1":2131,"PHASE2":2133,"PHASE3":2139,"PHASE4":2141,"NA":2143},{"trials":2130,"activeCount":92},[],{"trials":2132,"activeCount":92},[],{"trials":2134,"activeCount":92},[2135],{"nctId":2108,"briefTitle":2109,"status":664,"phases":2136,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":9,"conditions":2137,"interventions":2138},[81,82],[2114,2115,2116],[2099,2118,2119,2120],{"trials":2140,"activeCount":92},[],{"trials":2142,"activeCount":92},[],{"trials":2144,"activeCount":92},[],{"intervention":2119,"totalTrials":209,"cells":2146},{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2151,"PHASE3":2157,"PHASE4":2159,"NA":2161},{"trials":2148,"activeCount":92},[],{"trials":2150,"activeCount":92},[],{"trials":2152,"activeCount":92},[2153],{"nctId":2108,"briefTitle":2109,"status":664,"phases":2154,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":9,"conditions":2155,"interventions":2156},[81,82],[2114,2115,2116],[2099,2118,2119,2120],{"trials":2158,"activeCount":92},[],{"trials":2160,"activeCount":92},[],{"trials":2162,"activeCount":92},[],{"intervention":2120,"totalTrials":209,"cells":2164},{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2175,"PHASE4":2177,"NA":2179},{"trials":2166,"activeCount":92},[],{"trials":2168,"activeCount":92},[],{"trials":2170,"activeCount":92},[2171],{"nctId":2108,"briefTitle":2109,"status":664,"phases":2172,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":9,"conditions":2173,"interventions":2174},[81,82],[2114,2115,2116],[2099,2118,2119,2120],{"trials":2176,"activeCount":92},[],{"trials":2178,"activeCount":92},[],{"trials":2180,"activeCount":92},[],{"intervention":2182,"totalTrials":209,"cells":2183},"bryostatin 1",{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2185,"activeCount":92},[],{"trials":2187,"activeCount":92},[],{"trials":2189,"activeCount":92},[2190],{"nctId":2191,"briefTitle":2192,"status":664,"phases":2193,"completion":2194,"start":2195,"conditions":2196,"interventions":2197},"NCT00005056","Bryostatin 1 In Treating Patients With Progressive Kidney Cancer",[82],"2006-07","1999-03",[1337],[2182],{"trials":2199,"activeCount":92},[],{"trials":2201,"activeCount":92},[],{"trials":2203,"activeCount":92},[],{"intervention":2205,"totalTrials":88,"cells":2206},"multikinase inhibitor AT9283",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2229,"PHASE3":2231,"PHASE4":2233,"NA":2235},{"trials":2208,"activeCount":92},[],{"trials":2210,"activeCount":92},[2211,2218],{"nctId":2212,"briefTitle":2213,"status":664,"phases":2214,"primaryCompletion":1126,"completion":1126,"start":2215,"enrollment":20,"conditions":2216,"interventions":2217},"NCT01431664","AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia",[81],"2011-09",[1036],[2205],{"nctId":2219,"briefTitle":2220,"status":664,"phases":2221,"primaryCompletion":2222,"completion":2223,"start":2224,"enrollment":2225,"conditions":2226,"interventions":2228},"NCT00985868","AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors",[81],"2016-01-25","2019-11-20","2009-09",33,[2227],"Unspecified Childhood Solid Tumor, Protocol Specific",[2205],{"trials":2230,"activeCount":92},[],{"trials":2232,"activeCount":92},[],{"trials":2234,"activeCount":92},[],{"trials":2236,"activeCount":92},[],{"intervention":1426,"totalTrials":88,"cells":2238},{"EARLY_PHASE1":2239,"PHASE1":2241,"PHASE2":2258,"PHASE3":2260,"PHASE4":2262,"NA":2264},{"trials":2240,"activeCount":92},[],{"trials":2242,"activeCount":92},[2243,2247],{"nctId":1417,"briefTitle":1418,"status":664,"phases":2244,"primaryCompletion":1420,"completion":1420,"start":975,"enrollment":1421,"conditions":2245,"interventions":2246},[81],[1423],[1425,1426,1427,1410],{"nctId":2248,"briefTitle":2249,"status":664,"phases":2250,"primaryCompletion":2251,"completion":2251,"start":2252,"enrollment":2253,"conditions":2254,"interventions":2255},"NCT01222221","Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[81],"2015-02","2010-07",45,[1423],[2256,2257,1426],"glioblastoma multiforme multipeptide vaccine IMA950","sargramostim",{"trials":2259,"activeCount":92},[],{"trials":2261,"activeCount":92},[],{"trials":2263,"activeCount":92},[],{"trials":2265,"activeCount":92},[],{"intervention":2267,"totalTrials":209,"cells":2268},"Aurora B\u002FC kinase inhibitor GSK1070916A",{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2282,"PHASE3":2284,"PHASE4":2286,"NA":2288},{"trials":2270,"activeCount":92},[],{"trials":2272,"activeCount":92},[2273],{"nctId":2274,"briefTitle":2275,"status":664,"phases":2276,"primaryCompletion":2277,"completion":2277,"start":2278,"enrollment":2279,"conditions":2280,"interventions":2281},"NCT01118611","Aurora B\u002FC Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors",[81],"2013-03","2010-03",38,[30],[2267],{"trials":2283,"activeCount":92},[],{"trials":2285,"activeCount":92},[],{"trials":2287,"activeCount":92},[],{"trials":2289,"activeCount":92},[],{"intervention":2291,"totalTrials":209,"cells":2292},"angiogenesis inhibitor GSAO",{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2305,"PHASE3":2307,"PHASE4":2309,"NA":2311},{"trials":2294,"activeCount":92},[],{"trials":2296,"activeCount":92},[2297],{"nctId":2298,"briefTitle":2299,"status":1001,"phases":2300,"primaryCompletion":2301,"completion":2301,"start":2302,"enrollment":1712,"conditions":2303,"interventions":2304},"NCT01147029","GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy",[81],"2012-04","2008-01",[30],[2291],{"trials":2306,"activeCount":92},[],{"trials":2308,"activeCount":92},[],{"trials":2310,"activeCount":92},[],{"trials":2312,"activeCount":92},[],{"intervention":761,"totalTrials":209,"cells":2314},{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2316,"activeCount":92},[],{"trials":2318,"activeCount":92},[2319],{"nctId":753,"briefTitle":754,"status":664,"phases":2320,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":2321,"interventions":2322},[81],[511],[761,722],{"trials":2324,"activeCount":92},[],{"trials":2326,"activeCount":92},[],{"trials":2328,"activeCount":92},[],{"trials":2330,"activeCount":92},[],{"intervention":2332,"totalTrials":209,"cells":2333},"Chi Lob 7\u002F4",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2347,"PHASE3":2349,"PHASE4":2351,"NA":2353},{"trials":2335,"activeCount":92},[],{"trials":2337,"activeCount":92},[2338],{"nctId":2339,"briefTitle":2340,"status":664,"phases":2341,"primaryCompletion":756,"completion":756,"start":1508,"enrollment":2342,"conditions":2343,"interventions":2346},"NCT01561911","A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7\u002F4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment",[81],29,[22,452,16,2344,2345],"Non-Hodgkin","B-Cell",[2332],{"trials":2348,"activeCount":92},[],{"trials":2350,"activeCount":92},[],{"trials":2352,"activeCount":92},[],{"trials":2354,"activeCount":92},[],{"intervention":2356,"totalTrials":209,"cells":2357},"EBNA1 C-terminal\u002FLMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine",{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2372,"PHASE3":2374,"PHASE4":2376,"NA":2378},{"trials":2359,"activeCount":92},[],{"trials":2361,"activeCount":92},[2362],{"nctId":2363,"briefTitle":2364,"status":664,"phases":2365,"primaryCompletion":2366,"completion":2366,"start":1564,"enrollment":2367,"conditions":2368,"interventions":2371},"NCT01147991","Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer",[81],"2011-04",16,[201,669,16,2369,2370],"Lymphoproliferative Disorder","Nonneoplastic Condition",[2356],{"trials":2373,"activeCount":92},[],{"trials":2375,"activeCount":92},[],{"trials":2377,"activeCount":92},[],{"trials":2379,"activeCount":92},[],{"intervention":2381,"totalTrials":209,"cells":2382},"Vandetanib, Selumetinib",{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2397,"PHASE3":2399,"PHASE4":2401,"NA":2403},{"trials":2384,"activeCount":92},[],{"trials":2386,"activeCount":92},[2387],{"nctId":2388,"briefTitle":2389,"status":664,"phases":2390,"primaryCompletion":2391,"completion":2391,"start":2392,"enrollment":2393,"conditions":2394,"interventions":2396},"NCT01586624","A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)",[81],"2020-06-11","2012-01-10",61,[22,2395],"Non Small Cell Lung Cancer",[2381,2381,2381,2381,2381,2381,2381,2381],{"trials":2398,"activeCount":92},[],{"trials":2400,"activeCount":92},[],{"trials":2402,"activeCount":92},[],{"trials":2404,"activeCount":92},[],{"intervention":629,"totalTrials":209,"cells":2406},{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2415,"PHASE3":2417,"PHASE4":2419,"NA":2421},{"trials":2408,"activeCount":92},[],{"trials":2410,"activeCount":92},[2411],{"nctId":616,"briefTitle":617,"status":618,"phases":2412,"primaryCompletion":620,"start":621,"enrollment":113,"conditions":2413,"interventions":2414},[81],[16,623],[625,626,627,628,608,629],{"trials":2416,"activeCount":92},[],{"trials":2418,"activeCount":92},[],{"trials":2420,"activeCount":92},[],{"trials":2422,"activeCount":92},[],{"intervention":2424,"totalTrials":209,"cells":2425},"suramin",{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2438,"PHASE3":2440,"PHASE4":2442,"NA":2444},{"trials":2427,"activeCount":92},[],{"trials":2429,"activeCount":92},[2430],{"nctId":2431,"briefTitle":2432,"status":664,"phases":2433,"completion":2434,"start":2435,"enrollment":10,"conditions":2436,"interventions":2437},"NCT00006476","Suramin in Treating Patients With Recurrent Bladder Cancer",[81],"2007-10","2000-10",[502],[2424],{"trials":2439,"activeCount":92},[],{"trials":2441,"activeCount":92},[],{"trials":2443,"activeCount":92},[],{"trials":2445,"activeCount":92},[],{"intervention":2447,"totalTrials":209,"cells":2448},"boron phenylalanine",{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2461,"PHASE3":2463,"PHASE4":2465,"NA":2467},{"trials":2450,"activeCount":92},[],{"trials":2452,"activeCount":92},[2453],{"nctId":2454,"briefTitle":2455,"status":1001,"phases":2456,"primaryCompletion":2457,"completion":2457,"start":2434,"enrollment":1589,"conditions":2458,"interventions":2459},"NCT01233492","Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme",[81],"2013-09",[1423],[2447,2460],"mannitol",{"trials":2462,"activeCount":92},[],{"trials":2464,"activeCount":92},[],{"trials":2466,"activeCount":92},[],{"trials":2468,"activeCount":92},[],{"intervention":2460,"totalTrials":209,"cells":2470},{"EARLY_PHASE1":2471,"PHASE1":2473,"PHASE2":2479,"PHASE3":2481,"PHASE4":2483,"NA":2485},{"trials":2472,"activeCount":92},[],{"trials":2474,"activeCount":92},[2475],{"nctId":2454,"briefTitle":2455,"status":1001,"phases":2476,"primaryCompletion":2457,"completion":2457,"start":2434,"enrollment":1589,"conditions":2477,"interventions":2478},[81],[1423],[2447,2460],{"trials":2480,"activeCount":92},[],{"trials":2482,"activeCount":92},[],{"trials":2484,"activeCount":92},[],{"trials":2486,"activeCount":92},[],{"intervention":1006,"totalTrials":209,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2497,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2490,"activeCount":92},[],{"trials":2492,"activeCount":92},[2493],{"nctId":999,"briefTitle":1000,"status":1001,"phases":2494,"primaryCompletion":757,"completion":757,"start":1003,"enrollment":9,"conditions":2495,"interventions":2496},[81],[19,731,201,898,33,511,30],[1006,1007,626,1008],{"trials":2498,"activeCount":92},[],{"trials":2500,"activeCount":92},[],{"trials":2502,"activeCount":92},[],{"trials":2504,"activeCount":92},[],{"intervention":1007,"totalTrials":209,"cells":2506},{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2515,"PHASE3":2517,"PHASE4":2519,"NA":2521},{"trials":2508,"activeCount":92},[],{"trials":2510,"activeCount":92},[2511],{"nctId":999,"briefTitle":1000,"status":1001,"phases":2512,"primaryCompletion":757,"completion":757,"start":1003,"enrollment":9,"conditions":2513,"interventions":2514},[81],[19,731,201,898,33,511,30],[1006,1007,626,1008],{"trials":2516,"activeCount":92},[],{"trials":2518,"activeCount":92},[],{"trials":2520,"activeCount":92},[],{"trials":2522,"activeCount":92},[],{"intervention":2524,"totalTrials":209,"cells":2525},"MVA-EBNA1\u002FLMP2 vaccine",{"EARLY_PHASE1":2526,"PHASE1":2528,"PHASE2":2540,"PHASE3":2542,"PHASE4":2544,"NA":2546},{"trials":2527,"activeCount":92},[],{"trials":2529,"activeCount":92},[2530],{"nctId":2531,"briefTitle":2532,"status":664,"phases":2533,"primaryCompletion":2534,"completion":2534,"start":2277,"enrollment":2535,"conditions":2536,"interventions":2539},"NCT01800071","A Phase Ib Trial of MVA-EBNA1\u002FLMP2 Vaccine in Nasopharyngeal Carcinoma",[81],"2017-03-10",22,[2537,2538],"Nasopharyngeal Cancer","Epstein Barr Virus Infections",[2524],{"trials":2541,"activeCount":92},[],{"trials":2543,"activeCount":92},[],{"trials":2545,"activeCount":92},[],{"trials":2547,"activeCount":92},[],{"intervention":2549,"totalTrials":209,"cells":2550},"AST-VAC2",{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2565,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2552,"activeCount":92},[],{"trials":2554,"activeCount":92},[2555],{"nctId":2556,"briefTitle":2557,"status":664,"phases":2558,"primaryCompletion":2559,"completion":2559,"start":2560,"enrollment":2561,"conditions":2562,"interventions":2564},"NCT03371485","AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer",[81],"2022-08-08","2018-05-29",9,[2563],"Advanced Non-small Cell Lung Cancer",[2549],{"trials":2566,"activeCount":92},[],{"trials":2568,"activeCount":92},[],{"trials":2570,"activeCount":92},[],{"trials":2572,"activeCount":92},[],{"intervention":1425,"totalTrials":209,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2589},{"trials":2576,"activeCount":92},[],{"trials":2578,"activeCount":92},[2579],{"nctId":1417,"briefTitle":1418,"status":664,"phases":2580,"primaryCompletion":1420,"completion":1420,"start":975,"enrollment":1421,"conditions":2581,"interventions":2582},[81],[1423],[1425,1426,1427,1410],{"trials":2584,"activeCount":92},[],{"trials":2586,"activeCount":92},[],{"trials":2588,"activeCount":92},[],{"trials":2590,"activeCount":92},[],{"intervention":2256,"totalTrials":209,"cells":2592},{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2601,"PHASE3":2603,"PHASE4":2605,"NA":2607},{"trials":2594,"activeCount":92},[],{"trials":2596,"activeCount":92},[2597],{"nctId":2248,"briefTitle":2249,"status":664,"phases":2598,"primaryCompletion":2251,"completion":2251,"start":2252,"enrollment":2253,"conditions":2599,"interventions":2600},[81],[1423],[2256,2257,1426],{"trials":2602,"activeCount":92},[],{"trials":2604,"activeCount":92},[],{"trials":2606,"activeCount":92},[],{"trials":2608,"activeCount":92},[],{"intervention":2257,"totalTrials":209,"cells":2610},{"EARLY_PHASE1":2611,"PHASE1":2613,"PHASE2":2619,"PHASE3":2621,"PHASE4":2623,"NA":2625},{"trials":2612,"activeCount":92},[],{"trials":2614,"activeCount":92},[2615],{"nctId":2248,"briefTitle":2249,"status":664,"phases":2616,"primaryCompletion":2251,"completion":2251,"start":2252,"enrollment":2253,"conditions":2617,"interventions":2618},[81],[1423],[2256,2257,1426],{"trials":2620,"activeCount":92},[],{"trials":2622,"activeCount":92},[],{"trials":2624,"activeCount":92},[],{"trials":2626,"activeCount":92},[],{"intervention":2628,"totalTrials":209,"cells":2629},"DI-B4",{"EARLY_PHASE1":2630,"PHASE1":2632,"PHASE2":2645,"PHASE3":2647,"PHASE4":2649,"NA":2651},{"trials":2631,"activeCount":92},[],{"trials":2633,"activeCount":92},[2634],{"nctId":2635,"briefTitle":2636,"status":664,"phases":2637,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":2640,"conditions":2641,"interventions":2644},"NCT01805375","A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies",[81],"2017-12-14","2013-04",28,[2642,2115,2643],"Indolent B-cell Lymphoma","Waldenström Macroglobulinaemia",[2628],{"trials":2646,"activeCount":92},[],{"trials":2648,"activeCount":92},[],{"trials":2650,"activeCount":92},[],{"trials":2652,"activeCount":92},[],{"intervention":1020,"totalTrials":209,"cells":2654},{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2663,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2656,"activeCount":92},[],{"trials":2658,"activeCount":92},[2659],{"nctId":1010,"briefTitle":1011,"status":664,"phases":2660,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":1015,"conditions":2661,"interventions":2662},[81],[1017],[1019,1020,1021],{"trials":2664,"activeCount":92},[],{"trials":2666,"activeCount":92},[],{"trials":2668,"activeCount":92},[],{"trials":2670,"activeCount":92},[],{"intervention":1021,"totalTrials":209,"cells":2672},{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2681,"PHASE3":2683,"PHASE4":2685,"NA":2687},{"trials":2674,"activeCount":92},[],{"trials":2676,"activeCount":92},[2677],{"nctId":1010,"briefTitle":1011,"status":664,"phases":2678,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":1015,"conditions":2679,"interventions":2680},[81],[1017],[1019,1020,1021],{"trials":2682,"activeCount":92},[],{"trials":2684,"activeCount":92},[],{"trials":2686,"activeCount":92},[],{"trials":2688,"activeCount":92},[],{"intervention":2690,"totalTrials":209,"cells":2691},"AZD0424",{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2705,"PHASE3":2707,"PHASE4":2709,"NA":2711},{"trials":2693,"activeCount":92},[],{"trials":2695,"activeCount":92},[2696],{"nctId":2697,"briefTitle":2698,"status":1001,"phases":2699,"primaryCompletion":2700,"completion":2700,"start":2701,"enrollment":2702,"conditions":2703,"interventions":2704},"NCT01668550","A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours",[81],"2016-05","2012-10",43,[398],[2690],{"trials":2706,"activeCount":92},[],{"trials":2708,"activeCount":92},[],{"trials":2710,"activeCount":92},[],{"trials":2712,"activeCount":92},[],{"intervention":2714,"totalTrials":209,"cells":2715},"AZD3965",{"EARLY_PHASE1":2716,"PHASE1":2718,"PHASE2":2732,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2717,"activeCount":92},[],{"trials":2719,"activeCount":92},[2720],{"nctId":2721,"briefTitle":2722,"status":664,"phases":2723,"primaryCompletion":2724,"completion":2724,"start":2725,"enrollment":2726,"conditions":2727,"interventions":2731},"NCT01791595","A Phase I Trial of AZD3965 in Patients With Advanced Cancer",[81],"2020-11-17","2013-04-23",53,[2728,2729,2730],"Adult Solid Tumor","Diffuse Large B Cell Lymphoma","Burkitt Lymphoma",[2714,2714,2714,2714,2714,2714,2714],{"trials":2733,"activeCount":92},[],{"trials":2735,"activeCount":92},[],{"trials":2737,"activeCount":92},[],{"trials":2739,"activeCount":92},[],{"intervention":2741,"totalTrials":209,"cells":2742},"AT13148",{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2755,"PHASE3":2757,"PHASE4":2759,"NA":2761},{"trials":2744,"activeCount":92},[],{"trials":2746,"activeCount":92},[2747],{"nctId":2748,"briefTitle":2749,"status":664,"phases":2750,"primaryCompletion":2751,"completion":2751,"start":2752,"enrollment":1034,"conditions":2753,"interventions":2754},"NCT01585701","Phase I Study of AT13148, a Novel AGC Kinase Inhibitor",[81],"2018-01-10","2012-05",[398],[2741],{"trials":2756,"activeCount":92},[],{"trials":2758,"activeCount":92},[],{"trials":2760,"activeCount":92},[],{"trials":2762,"activeCount":92},[],{"intervention":2764,"totalTrials":209,"cells":2765},"DMXAA",{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2780,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2767,"activeCount":92},[],{"trials":2769,"activeCount":92},[2770],{"nctId":2771,"briefTitle":2772,"status":664,"phases":2773,"primaryCompletion":2774,"completion":2774,"start":2775,"enrollment":2776,"conditions":2777,"interventions":2779},"NCT00863733","Study of DMXAA (Now Known as ASA404) in Solid Tumors",[81],"2000-03","1996-05",63,[2778],"Solid Tumors",[2764],{"trials":2781,"activeCount":92},[],{"trials":2783,"activeCount":92},[],{"trials":2785,"activeCount":92},[],{"trials":2787,"activeCount":92},[],{"intervention":2789,"totalTrials":209,"cells":2790},"MOv18 IgE",{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2806,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2792,"activeCount":92},[],{"trials":2794,"activeCount":92},[2795],{"nctId":2796,"briefTitle":2797,"status":664,"phases":2798,"primaryCompletion":2799,"completion":2800,"start":2801,"enrollment":2802,"conditions":2803,"interventions":2805},"NCT02546921","Phase I Study of MOv18 IgE",[81],"2021-06-22","2021-07-30","2016-02-16",26,[2804],"Human Cancers",[2789,2789,2789,2789,2789,2789,2789],{"trials":2807,"activeCount":92},[],{"trials":2809,"activeCount":92},[],{"trials":2811,"activeCount":92},[],{"trials":2813,"activeCount":92},[],{"intervention":2815,"totalTrials":209,"cells":2816},"NG-nitro-L-arginine",{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2828,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2818,"activeCount":92},[],{"trials":2820,"activeCount":92},[2821],{"nctId":2822,"briefTitle":2823,"status":1001,"phases":2824,"primaryCompletion":2825,"completion":2825,"start":2366,"enrollment":31,"conditions":2826,"interventions":2827},"NCT01324115","NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors",[81],"2012-09",[30],[2815],{"trials":2829,"activeCount":92},[],{"trials":2831,"activeCount":92},[],{"trials":2833,"activeCount":92},[],{"trials":2835,"activeCount":92},[],{"intervention":2837,"totalTrials":988,"cells":2838},"polymorphism analysis",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2845,"PHASE4":2847,"NA":2849},{"trials":2840,"activeCount":92},[],{"trials":2842,"activeCount":92},[],{"trials":2844,"activeCount":92},[],{"trials":2846,"activeCount":92},[],{"trials":2848,"activeCount":92},[],{"trials":2850,"activeCount":92},[2851,2858,2869,2878,2884,2892,2898,2905],{"nctId":2852,"briefTitle":2853,"status":618,"phases":2854,"start":636,"enrollment":2855,"conditions":2856,"interventions":2857},"NCT00757965","Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom",[],2000,[731],[2837],{"nctId":2859,"briefTitle":2860,"status":618,"phases":2861,"start":636,"enrollment":2862,"conditions":2863,"interventions":2867},"NCT00757614","Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom",[],14000,[502,1423,2864,2865,1337,16,1566,511,2866],"Esophageal Cancer","Intraocular Melanoma","Transitional Cell Cancer of the Renal Pelvis and Ureter",[2868,2837],"DNA analysis",{"nctId":2870,"briefTitle":2871,"status":618,"phases":2872,"primaryCompletion":1044,"start":2873,"conditions":2874,"interventions":2875},"NCT00896818","Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and Friends",[],"2005-01",[19],[2868,2876,2877,2837],"genetic linkage analysis","loss of heterozygosity analysis",{"nctId":2879,"briefTitle":2880,"status":618,"phases":2881,"start":636,"enrollment":2855,"conditions":2882,"interventions":2883},"NCT00757263","Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom",[],[33],[2837],{"nctId":2885,"briefTitle":2886,"status":618,"phases":2887,"start":636,"enrollment":2888,"conditions":2889,"interventions":2891},"NCT00757991","Blood Samples From Healthy Volunteers for Genetic Studies in the East Anglia Region of the United Kingdom",[],4000,[2890],"Healthy, no Evidence of Disease",[2837],{"nctId":2893,"briefTitle":2894,"status":618,"phases":2895,"start":636,"enrollment":2855,"conditions":2896,"interventions":2897},"NCT00758173","Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom",[],[981],[2837],{"nctId":2899,"briefTitle":2900,"status":618,"phases":2901,"start":636,"enrollment":2902,"conditions":2903,"interventions":2904},"NCT00757211","Study of Genes and Environment in Patients With Breast Cancer in the East Anglia Region of the United Kingdom",[],6000,[19],[2837],{"nctId":2906,"briefTitle":2907,"status":618,"phases":2908,"start":636,"enrollment":2855,"conditions":2909,"interventions":2910},"NCT00758056","Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom",[],[507],[2837],{"intervention":2868,"totalTrials":609,"cells":2912},{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2917,"PHASE3":2919,"PHASE4":2921,"NA":2923},{"trials":2914,"activeCount":92},[],{"trials":2916,"activeCount":92},[],{"trials":2918,"activeCount":92},[],{"trials":2920,"activeCount":92},[],{"trials":2922,"activeCount":92},[],{"trials":2924,"activeCount":92},[2925,2937,2941,2945],{"nctId":2926,"briefTitle":2927,"status":618,"phases":2928,"primaryCompletion":2929,"start":2930,"enrollment":2888,"conditions":2931,"interventions":2933},"NCT00963092","Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer",[],"2010-12","2002-08",[2932,2864,201],"Adenocarcinoma of the Gastroesophageal Junction",[2868,2934,2935,2936],"RNA analysis","microarray analysis","protein analysis",{"nctId":2859,"briefTitle":2860,"status":618,"phases":2938,"start":636,"enrollment":2862,"conditions":2939,"interventions":2940},[],[502,1423,2864,2865,1337,16,1566,511,2866],[2868,2837],{"nctId":2870,"briefTitle":2871,"status":618,"phases":2942,"primaryCompletion":1044,"start":2873,"conditions":2943,"interventions":2944},[],[19],[2868,2876,2877,2837],{"nctId":2946,"briefTitle":2947,"status":618,"phases":2948,"primaryCompletion":2949,"start":2950,"enrollment":2951,"conditions":2952,"interventions":2953},"NCT00967954","Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer",[85],"2013-08","2008-09",120,[981],[2954,2955,2868,2934,2956,1427],"antiandrogen therapy","releasing hormone agonist therapy","comparative genomic hybridization",{"intervention":1427,"totalTrials":13,"cells":2958},{"EARLY_PHASE1":2959,"PHASE1":2961,"PHASE2":2967,"PHASE3":2969,"PHASE4":2971,"NA":2973},{"trials":2960,"activeCount":92},[],{"trials":2962,"activeCount":92},[2963],{"nctId":1417,"briefTitle":1418,"status":664,"phases":2964,"primaryCompletion":1420,"completion":1420,"start":975,"enrollment":1421,"conditions":2965,"interventions":2966},[81],[1423],[1425,1426,1427,1410],{"trials":2968,"activeCount":92},[],{"trials":2970,"activeCount":92},[],{"trials":2972,"activeCount":92},[],{"trials":2974,"activeCount":92},[2975,2979],{"nctId":2946,"briefTitle":2947,"status":618,"phases":2976,"primaryCompletion":2949,"start":2950,"enrollment":2951,"conditions":2977,"interventions":2978},[85],[981],[2954,2955,2868,2934,2956,1427],{"nctId":2980,"briefTitle":2981,"status":618,"phases":2982,"primaryCompletion":2983,"start":2984,"conditions":2985,"interventions":2986},"NCT00967889","Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer",[],"2011-06","2002-01",[981],[1427,2936],{"intervention":2934,"totalTrials":88,"cells":2988},{"EARLY_PHASE1":2989,"PHASE1":2991,"PHASE2":2993,"PHASE3":2995,"PHASE4":2997,"NA":2999},{"trials":2990,"activeCount":92},[],{"trials":2992,"activeCount":92},[],{"trials":2994,"activeCount":92},[],{"trials":2996,"activeCount":92},[],{"trials":2998,"activeCount":92},[],{"trials":3000,"activeCount":92},[3001,3005],{"nctId":2926,"briefTitle":2927,"status":618,"phases":3002,"primaryCompletion":2929,"start":2930,"enrollment":2888,"conditions":3003,"interventions":3004},[],[2932,2864,201],[2868,2934,2935,2936],{"nctId":2946,"briefTitle":2947,"status":618,"phases":3006,"primaryCompletion":2949,"start":2950,"enrollment":2951,"conditions":3007,"interventions":3008},[85],[981],[2954,2955,2868,2934,2956,1427],{"intervention":2936,"totalTrials":88,"cells":3010},{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3017,"PHASE4":3019,"NA":3021},{"trials":3012,"activeCount":92},[],{"trials":3014,"activeCount":92},[],{"trials":3016,"activeCount":92},[],{"trials":3018,"activeCount":92},[],{"trials":3020,"activeCount":92},[],{"trials":3022,"activeCount":92},[3023,3027],{"nctId":2926,"briefTitle":2927,"status":618,"phases":3024,"primaryCompletion":2929,"start":2930,"enrollment":2888,"conditions":3025,"interventions":3026},[],[2932,2864,201],[2868,2934,2935,2936],{"nctId":2980,"briefTitle":2981,"status":618,"phases":3028,"primaryCompletion":2983,"start":2984,"conditions":3029,"interventions":3030},[],[981],[1427,2936],{"intervention":2935,"totalTrials":209,"cells":3032},{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3037,"PHASE3":3039,"PHASE4":3041,"NA":3043},{"trials":3034,"activeCount":92},[],{"trials":3036,"activeCount":92},[],{"trials":3038,"activeCount":92},[],{"trials":3040,"activeCount":92},[],{"trials":3042,"activeCount":92},[],{"trials":3044,"activeCount":92},[3045],{"nctId":2926,"briefTitle":2927,"status":618,"phases":3046,"primaryCompletion":2929,"start":2930,"enrollment":2888,"conditions":3047,"interventions":3048},[],[2932,2864,201],[2868,2934,2935,2936],{"intervention":2876,"totalTrials":209,"cells":3050},{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3055,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3052,"activeCount":92},[],{"trials":3054,"activeCount":92},[],{"trials":3056,"activeCount":92},[],{"trials":3058,"activeCount":92},[],{"trials":3060,"activeCount":92},[],{"trials":3062,"activeCount":92},[3063],{"nctId":2870,"briefTitle":2871,"status":618,"phases":3064,"primaryCompletion":1044,"start":2873,"conditions":3065,"interventions":3066},[],[19],[2868,2876,2877,2837],{"intervention":2877,"totalTrials":209,"cells":3068},{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3073,"PHASE3":3075,"PHASE4":3077,"NA":3079},{"trials":3070,"activeCount":92},[],{"trials":3072,"activeCount":92},[],{"trials":3074,"activeCount":92},[],{"trials":3076,"activeCount":92},[],{"trials":3078,"activeCount":92},[],{"trials":3080,"activeCount":92},[3081],{"nctId":2870,"briefTitle":2871,"status":618,"phases":3082,"primaryCompletion":1044,"start":2873,"conditions":3083,"interventions":3084},[],[19],[2868,2876,2877,2837],{"intervention":2954,"totalTrials":209,"cells":3086},{"EARLY_PHASE1":3087,"PHASE1":3089,"PHASE2":3091,"PHASE3":3093,"PHASE4":3095,"NA":3097},{"trials":3088,"activeCount":92},[],{"trials":3090,"activeCount":92},[],{"trials":3092,"activeCount":92},[],{"trials":3094,"activeCount":92},[],{"trials":3096,"activeCount":92},[],{"trials":3098,"activeCount":92},[3099],{"nctId":2946,"briefTitle":2947,"status":618,"phases":3100,"primaryCompletion":2949,"start":2950,"enrollment":2951,"conditions":3101,"interventions":3102},[85],[981],[2954,2955,2868,2934,2956,1427],{"intervention":2955,"totalTrials":209,"cells":3104},{"EARLY_PHASE1":3105,"PHASE1":3107,"PHASE2":3109,"PHASE3":3111,"PHASE4":3113,"NA":3115},{"trials":3106,"activeCount":92},[],{"trials":3108,"activeCount":92},[],{"trials":3110,"activeCount":92},[],{"trials":3112,"activeCount":92},[],{"trials":3114,"activeCount":92},[],{"trials":3116,"activeCount":92},[3117],{"nctId":2946,"briefTitle":2947,"status":618,"phases":3118,"primaryCompletion":2949,"start":2950,"enrollment":2951,"conditions":3119,"interventions":3120},[85],[981],[2954,2955,2868,2934,2956,1427],{"intervention":2956,"totalTrials":209,"cells":3122},{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3129,"PHASE4":3131,"NA":3133},{"trials":3124,"activeCount":92},[],{"trials":3126,"activeCount":92},[],{"trials":3128,"activeCount":92},[],{"trials":3130,"activeCount":92},[],{"trials":3132,"activeCount":92},[],{"trials":3134,"activeCount":92},[3135],{"nctId":2946,"briefTitle":2947,"status":618,"phases":3136,"primaryCompletion":2949,"start":2950,"enrollment":2951,"conditions":3137,"interventions":3138},[85],[981],[2954,2955,2868,2934,2956,1427]]